Avangrid (NYSE:AGR) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.34 by 41.18 percent. This is a 37.14 percent increase over earnings of $0.35 per share from the same period last year.
Corcept Therapeutics Provides Financial Update And Announces $200M Stock Repurchase Program; Sees Q4 Revenue $135.4M Vs $127.85M Est.; FY23 Revenue $482.4M Vs $474.82M Est.; FY24 Revenue $600M–$630M Vs $513.85M Est.
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating
